title: Endovascular treatment of external iliac artery occlusive disease: midterm results.
abstract: OBJECTIVE
  To report midterm outcomes for endovascular treatment of external iliac artery (EIA) occlusive disease and assess possible factors affecting patency.
  
  
  METHODS
  A retrospective analysis was conducted of 99 consecutive patients (91 men; mean age 67.3 years) with claudication (n=70) or critical limb ischemia (n=29) owing to occlusive EIA disease treated at our center from January 2005 to June 2012. The majority of lesions (79/108) were TASC A/B. Lesions were a mean 42.2 mm long (range 10-125); 43/108 affected the distal third of the EIA. Balloon angioplasty alone was performed in 7 limbs, while the remaining 101 lesions were stented (65 self-expanding, 24 balloon-expandable, and 12 covered). Clinical and hemodynamic follow-up was performed at 1, 3, 6, and 12 months after therapy and yearly thereafter. The factors examined were procedure characteristics and patency rates.
  
  
  RESULTS
  Over a median follow-up of 27.5 months (range 1-89), there were 2 (1.9%) early occlusions followed by a successful reintervention, 4 late occlusions, and 5 hemodynamic failures followed by 7 reinterventions. These events led to primary and secondary patency rates at 30 months of 89.7% and 94.1%, respectively. No differences in patency rates were detected according to age, clinical state, or comorbidity. Use of covered stents (p=0.006) was the only variable associated with lower primary patency rates.
  
  
  CONCLUSIONS
  Endovascular therapy to treat TASC A/B lesions of the EIA yielded good short and midterm patency and low early morbidity and mortality. Lesions involving the distal third of the EIA treated by simple angioplasty ± stenting fared worse. No clinical factors could be correlated with patency.
authors.affiliation: Servicio de Angiología y Cirugía Vascular, Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
authors.forename: Sergio
authors.initials: S
authors.lastname: Revuelta Suero
authors.forename: Isaac
authors.initials: I
authors.lastname: Martínez López
authors.forename: Manuel
authors.initials: M
authors.lastname: Hernando Rydings
authors.forename: Pablo
authors.initials: P
authors.lastname: Marqués de Marino
authors.forename: Ana
authors.initials: A
authors.lastname: Saiz Jerez
authors.forename: Manuela Maria
authors.initials: MM
authors.lastname: Hernández Mateo
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Serrano Hernando
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000800:Angioplasty, Balloon / Q000009:adverse effects; D003251:Constriction, Pathologic; D016638:Critical Illness; D005260:Female; D006801:Humans; D007083:Iliac Artery / Q000503:physiopathology; D007383:Intermittent Claudication / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D007511:Ischemia / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D011474:Prosthesis Design; D012189:Retrospective Studies; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D014654:Vascular Patency